ADAMTS13 and liver failure: Our group further evaluated changes in ADAMTS-13/VWF in patients with advanced chronic liver disease in relation to markers of endotoxemia such as LPS, confirming the strong association between decreased ADAMTS-13/VWF, chronic low-grade inflammation, and risk of liver failure.